Home › NDC Lookup › Ingredients › Selegiline Hydrochloride › 60505-3438-03
⚪image loading
(from DailyMed)

Selegiline Hydrochloride 5 mg Tablet, 60-count — NDC 60505-3438-3 (Billing 60505-3438-03)

by Apotex Corp. · 60 TABLET in 1 BOTTLE

This is a package of 60 tablets of Selegiline Hydrochloride 5 mg Tablet from Apotex Corp., marketed since Jul 1997 and currently FDA-listed; retail pharmacies pay about $0.7657 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 60505-3438-03
🏷️ FDA NDC (as labeled) 60505-3438-3 billing pads the package segment with a zero
This package
Contains60-count Cost per ea$0.7657 NADAC Per package$45.94 / 60 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.9342/unit · Part D plans $1.15/unit — full pricing hub ↓
Main listing for product 60505-3438 · Also comes in: 500 tablets 60505-3438-8
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 60505-3438-3 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
60505 labeler · 3438 product · 3 package
Package marketed since
Jul 6, 1997
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
60 EA per package
Barcode (UPC-A, from the NDC)
3 6050534383 6
Medicaid fills, this package
694 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 60505-3438-3
Product NDC 60505-3438
11-digit billing NDC 60505343803
NCPDP billing unit EA — each (per item)
Application # ANDA074871
SPL Set ID a15bc36b-3cd1-c169-0a76-80dc5ba14781
Established class (EPC) Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor
Mechanism of action Monoamine Oxidase Inhibitors; Monoamine Oxidase-B Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1997-07-06
Route ORAL
Dosage form TABLET
Substance SELEGILINE HYDROCHLORIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 012070
GCN 15600
HICL code 016483
Ingredient (HICL) Selegiline Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6A
Therapeutic class — specific (HIC3) Antiparkinsonism Drugs,Other
AHFS code 28:16.04.12
AHFS class Monoamine Oxidase Inhibitors
FDB label name SELEGILINE HCL 5 MG TABLET
FDB brand name Selegiline Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 012070
  • GCN: 15600
  • HICL (First Databank): 016483
  • AHFS class code: 28:16.04.12
Why two NDCs? The FDA registers this code as 60505-3438-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60505-3438-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name SELEGILINE HCL 5 MG TABLET Ingredient Selegiline Hcl
📖 What it is MedlinePlus · NLM

Selegiline is used to help control the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) in people who are taking levodopa and carbidopa combination (Sinemet). Selegiline may help people with Parkinson's disease by decreasing the dose of levodopa/carbidopa needed to control symptoms, stopping the effects of levodopa/carbidopa from wearing off between doses, and increasing the length of time that levodopa/carbidopa will continue to control symptoms. Selegiline is in a group of medications called monoamine o...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. The tablets, capsules and Zelapar are add-ons for Parkinson’s disease in people on levodopa/carbidopa whose response has worsened. The Emsam patch treats...
  • Take it in the morning before breakfast. With dry hands, peel back the foil, then place the tablet on your tongue, where it dissolves in seconds. Skip food and drink for 5 minutes...
  • With the Emsam patch at the 9 or 12 mg per 24 hours doses, you must avoid tyramine-rich foods such as aged cheese, cured meats and tap beer. Keep this up for 2 weeks after lowering...
  • Check with me first. Many antidepressants, some pain medicines, dextromethorphan and carbamazepine can be dangerous with selegiline. Decongestants like pseudoephedrine can raise yo...
📖 Read our full Selegiline guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
1
Nutrient depletion considerations

Selegiline may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Selegiline nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.766 $45.94 / 60 tablets
Medicaid paysCMS SDUD · 12 mo $0.9342 $56.05 / 60 tablets
Medicare drug plans payPart D · Q2 2026 $1.15 $69.13 / 60 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $1.105 $0.690
▼ Down 31% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
60505-3438-03 You're viewing this Main listing 60 TABLET in 1 BOTTLE $0.7657 / ea $45.94 1997-07-06 — Active
60505-3438-08 60505-3438-8 500 TABLET in 1 BOTTLE $0.8121 / ea $406.07 1997-07-06 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.7657 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 60-count package — 60 tablet in 1 bottle.
How does this package differ from NDC 60505-3438-08?
Both are Selegiline Hydrochloride 5 mg Tablet — the drug itself is identical. This page's package is the 60-count one, while NDC 60505-3438-08 is the 500 tablets package. Per-ea NADAC also differs: $0.7657 here vs $0.8121 for the 500 tablets pack.
What NDC number is used to bill for this package of Selegiline Hydrochloride 5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Selegiline Hydrochloride 5 mgthis 60505-3438-03 Apotex 60 tablets $0.766 AB Availability likely —
Selegiline Hydrochloride 5 mg 72319-0006-02 i3 60 tablets $0.766 AB Availability likely —
Selegiline Hydrochloride 5 mg 50090-2918-00 A-S 4 tablets — AB FDA listed —
Selegiline Hydrochloride 5 mg 60429-0176-60 Golden 60 tablets — AB FDA listed —
Selegiline Hydrochloride 5 mg 62135-0694-60 Chartwell 60 tablets — — FDA listed —
Selegiline Hydrochloride 5 mg 73141-0006-02 A2A 60 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1997
On the market since
Jul 1997
📍
2026
Currently FDA-listed
29 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Selegiline inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerApotex Corp.
Application holderAPOTEX INC
FDA applicationANDA074871 (ANDA)
Labeler code60505
First marketedJul 1997
Product typeHuman Prescription Drug
Portfolio313 products on file

More NDCs from Apotex Corp. labeler code 60505

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
694
Units reimbursed last 4 qtrs
54.1K
Gross reimbursed last 4 qtrs
$50.5K
Avg / prescription
$72.79
Avg / unit
$0.9342
Latest quarter Q4 2025
171Rx
Medicaid pays / ea
$0.9342
gross reimbursed
vs
NADAC / ea
$0.7657
acquisition cost
=
Spread
+$0.1685
+22% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
68% FFS 32% MCO
Fee-for-service · 469 Rx Managed care · 225 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 20,220 units · 103 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 634 units · 15.0 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 1,487 units · 11.8 per 100k residents IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 3,612 units · 38.9 per 100k residents NJ Massachusetts: 492 units · 7.0 per 100k residents MA California: 20,017 units · 51.4 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 3,110 units · 35.7 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 3,840 units · 17.0 per 100k residents FL
Units reimbursed · per 100k residents
7.0103
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 103 /100k
2 California 51.4 /100k
3 New Jersey 38.9 /100k
4 Virginia 35.7 /100k
5 Florida 17.0 /100k
6 Oregon 15.0 /100k
7 Illinois 11.8 /100k
8 Massachusetts 7.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
60 tablets this page60505-3438-03 694 Rx · $50,513
500 tablets60505-3438-08 No Medicaid data
Drug total (last 4 qtrs): 694 Rx · 54,072 units · $50,513 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 60505-3280-05 · Apotex 60505-3478-03 · Apotex →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.